According to Benzinga Pro, Eli Lilly's peer group average for short interest as a percentage of float is 4.12%, which means ...

BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...

Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes drug ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.

We recently compiled a list of the 10 Most Promising Dividend Stocks According to Hedge Funds. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...